课题基金 / 基金详情

ATP13A2 and Susceptibility to Neurodegeneration

ATP13A2 and Susceptibility to Neurodegeneration
ATP13A2 和神经退行性变的易感性
批准号:
10641796
负责人:
Sheila Fleming
金额:
$32.95万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-28 至 2025-06-30
关键词:
ATP phosphohydrolaseAccelerationAffectAgeAge MonthsAgingAreaBasal GangliaBehaviorBehavioralBioenergeticsBiogenesisBiological AssayBrainBrain regionCandidate Disease GeneCerebellumClassificationCorpus striatum structureDataDefectDevelopmentDiseaseEarly DiagnosisEarly identificationEarly treatmentEconomicsElderlyEnvironmentEnvironmental ExposureEnvironmental Risk FactorFinancial HardshipFunctional disorderGenesGeneticGenetic PolymorphismGenetic Predisposition to DiseaseHallervorden-Spatz SyndromeHealthHeavy MetalsHereditary Spastic ParaplegiaHeterozygoteHomeostasisHumanIn VitroInheritedInterventionIronKnockout MiceKnowledgeLRRK2 geneLewy BodiesLinkMaintenanceManganeseManganismMeasuresMetal exposureMidbrain structureMissionMitochondriaMusMutationNerve DegenerationNeurodegenerative DisordersNeuronal Ceroid-LipofuscinosisNeuronsOnset of illnessPARK8 genePARK9 geneParkinson DiseasePathologicPathologyPatientsPersonsPhysiologicalPopulationPredispositionPreventionPrevention strategyProteinsProteomicsPublic HealthQuality ControlQuality of lifeRegimenResearchRiskRisk FactorsRoleSyndromeTechniquesTestingToxic effectUnited States National Institutes of HealthVariantWorkZincage relatedage related neurodegenerationalpha synucleinbehavioral impairmentcohortdisabilityearly onsetgene environment interactiongenetic risk factorin vivolink proteinloss of functionloss of function mutationmitochondrial dysfunctionmutantneurotoxicneurotoxicitynigrostriatal degenerationnoveloverexpressionprotein degradationpublic health relevancerepairedresponsesynucleinopathytherapeutic targettherapeutically effectivetranslational potentialtreatment strategy

项目摘要

项目成果

Sheila Fleming的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract Age-related neurodegenerative diseases are an increasing health and economic threat for millions of people each year. Genetic susceptibility, environmental exposures, and age can all increase the risk of developing neurodegenerative conditions such as synucleinopathies and manganism. The ATPase ATP13A2 is associated with multiple age-related neurodegenerative conditions including Parkinson’s disease, the most common synucleinopathy, Neuronal Ceroid Lipofuscinosis, and manganism and may be an important protein linking key neurodegenerative disease risk factors. Identification of gene-environment interactions associated with neurodegeneration is an important step to early detection, prevention, and treatment. The objective of this proposal is to determine how ATP13A2 is involved in mitochondrial maintenance and how it interacts with environmental and genetic risk factors to cause neurodegeneration. It is hypothesized that loss of ATP13A2 function makes neurons more vulnerable to manganese and alpha-synuclein toxicity through mechanisms involved in mitochondrial maintenance including repair and clearance mechanisms. Further, this disruption may interact with aging and protein accumulation to produce enhanced neurodegeneration and behavioural dysfunction. Our recent data shows that loss of function of ATP13A2 in mice leads to an enhanced response to manganese and increased pathology in the brain. Guided by preliminary data this hypothesis will be tested by pursuing three specific aims: 1) Determine the impact of loss of ATP13A2 function on mitochondrial maintenance in vivo, 2) Assess the neurotoxic consequences of Mn exposure in the presence of ATP13A2 loss on mitochondrial function in brain and periphery, and 3) Identify the impact of loss of ATP13A2 function and increased alpha-synuclein burden on mitochondrial maintenance and bioenergetics in vivo. Results from these studies are expected to have a positive impact on our understanding of how gene-environment interactions can contribute to cellular dysfunction, neurodegeneration, and behavioral impairments.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.neuropharm.2021.108870
发表时间: 2022-01-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者: [Fleming, Sheila M., Davis, Ashley, Simons, Emily]
通讯作者: Simons, Emily
DOI: 10.1016/b978-0-323-85555-6.00002-3
发表时间: 2023
期刊: Handbook of clinical neurology
影响因子: --
作者: [Simons, Emily, Fleming, Sheila M]
通讯作者: Fleming, Sheila M
DOI: 10.3389/fneur.2023.1252400
发表时间: 2023
期刊: Frontiers in neurology
影响因子: 3.4
作者: []
通讯作者:
ATP13A2 and Susceptibility to Neurodegeneration
ATP13A2 and Susceptibility to Neurodegeneration
The interaction between ATP13A2 and alpha-synuclein in mice
  • 批准号:
    8320093
  • 项目类别:
  • 资助金额:
    $23.55万
  • 财政年份:
    2011
  • 负责人:
    Sheila Fleming
  • 依托单位:
The interaction between ATP13A2 and alpha-synuclein in mice
  • 批准号:
    8224462
  • 项目类别:
  • 资助金额:
    $19.63万
  • 财政年份:
    2011
  • 负责人:
    Sheila Fleming
  • 依托单位:
海外基金